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ABSTRACT
Background. Oral anticoagulation therapy (OAT) is the
choice treatment for thromboembolism prevention in atrial
fibrillation (AF), although data about OAT use in haemodialy-
sis (HD) patients with AF are contradictory.
Methods. The effect of OAT on the risk of mortality, stroke
and bleeding was prospectively evaluated in a population of
HD patients with AF. All the patients of 10 HD Italian centres
alive on 31 October 2010 with documented AF episode(s)
were recruited and followed-up for 2 years. OAT and antiplate-
let intake, age, dialytic age, comorbidities and percentage time
in the target international normalized ratio (INR) range
(target therapeutic range; TTR) were considered as predictors
of hazard of death, thromboembolic and bleeding events.
Results. At recruitment, 134 patients out of 290 were taking
OAT. During the follow-up, 115 patients died (4 strokes, 3
haemorrhagic and 1 thromboembolic). Antiplatelet therapy,
but not OAT, was associated with increased mortality (HR
1.71, CI 1.10–2.64, P = 0.02). The estimated survival of pa-
tients always taking OAT tended to be higher than that of pa-
tients who stopped taking (68.6 versus 49.6%, P = 0.07). OAT
was not correlated to a significant decreased risk of thrombo-
embolic events (HR 0.12, CI 0.00–3.59, P = 0.20), while it was
associated with an increased risk of bleeding (HR 3.96, CI
1.15–13.68, P = 0.03). Higher TTR was associated with a
reduced bleeding risk (HR 0.09, CI 0.01–0.76, P = 0.03), while
previous haemorrhagic events were associated with higher
haemorrhagic risk (HR 2.17, CI 1.09–4.35, P = 0.03).
Conclusions. In our population of HD patients with AF, the
mortality is very high. OAT is not associated with increased
mortality, while antiplatelet drugs are. OAT seems, on the con-
trary, associated with a better survival; however, it does not de-
crease the incidence of ischaemic stroke, whereas it increases
the incidence of bleeding. Bleeding risk is lower in subjects in
whom the INR is kept within the therapeutic range.
Keywords: atrial fibrillation, bleeding, haemodialysis, mortal-
ity, oral anticoagulation therapy, stroke
INTRODUCTION
The prevalence of atrial fibrillation (AF) in patients with
end-stage renal disease (ESRD) on haemodialysis (HD) is high
[1–4]. The presence of AF increases the risk of thromboembol-
ic stroke in the general population [5] and a similar phenom-
enon seems to occur in the population of ESRD patients [6, 7].
This is of particular concern given the fact that the risk of
stroke in the HD population is already increased by nearly
6-fold, even in the absence of AF [8]. The treatment of choice
© The Author 2014. Published by Oxford University Press
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for reducing thromboembolic risk in AF patients is oral anti-
coagulant therapy (OAT) with warfarin [9], but randomized
trials showing the beneficial effects of OAT on thromboembol-
ic risk excluded ESRD patients. An increased risk of stroke in
ESRD patients taking OAT was described [10, 11]. A Canadian
study, performed in elderly patients hospitalized for AF,
showed that HD patients did not benefit from warfarin
therapy with regard to ischaemic stroke, and that they had an
increased haemorrhagic risk [12]. In contrast, a Danish study
described a protective effect of warfarin on thromboembolic
events in HD patients, without an increment in bleeding [13].
A review of data from the Dialysis Outcomes and Practice Pat-
terns Study (DOPPS) showed that, in patients with AF, OAT
was associated with a slightly higher incidence of bleeding
than in non-OAT patients, while bleeding episodes rose dra-
matically in patients with a history of bleeding [14].
At the moment, there are no prospective studies regarding
the risk–benefit assessment of the use of warfarin in ESRD pa-
tients with AF and the argument is controversial. The purpose
of this study was to prospectively evaluate the effect of OAT on
the risk of mortality, stroke and bleeding in this population.
MATERIALS AND METHODS
All patients alive and under observation in 10 Italian HD
centres on 31 October 2010 were considered (N = 1529) and
their clinical charts revised for eligibility to the study. All sub-
jects with at least one documented paroxysmal (self-terminat-
ing) or persistent (required termination by pharmacological or
electrical cardioversion) AF episode, or with permanent AF
(arrhythmia that could not be interrupted spontaneously or by
pharmacological or electrical cardioversion), were recruited,
for a total of 290 patients.
At recruitment, data were collected on the presence of
hypertension, diabetes mellitus, dyslipidaemia, peripheral
artery disease, ischaemic heart disease, heart failure, previous
strokes and major bleeding episodes and on administration of
anticoagulants (warfarin and low-molecular-weight heparin)
and antiplatelets (aspirin, ticlopidine and clopidogrel) (see
Supplementary material for definitions).
Patients were prospectively followed-up for 2 years (until
31 October 2012 or death), with updates at each dialysis
session. The fresh onset of permanent AF, stroke (ischaemic or
haemorrhagic), bleeding, cardiovascular events (ischaemic and
heart failure episodes), antiplatelet and anticoagulant treat-
ment modifications were recorded.
In patients taking OAT, the international normalized ratio
(INR) values were assessed at least once a month. To deter-
mine the achieved intensity of anticoagulation and to assess
INR variability, the percentage time in the target INR range
(target therapeutic range; TTR) and its variance growth rate
(VGR; according to the Cannegieter formula) were also calcu-
lated [15, 16].
Thromboembolic and haemorrhagic risk were calculated
using the CHA2DS2VASc and the HASBLED scores ([17], see
Supplementary material for definitions). Procedures were per-
formed according to the Helsinki declaration for ethical
treatment of human subjects and approved by the local ethical
committee. Informed consent was obtained from the enrolled
subjects.
Statistical analysis
All data were centrally revised by clinical and statistical re-
viewers. Patients were considered under OAT at recruitment if
taking OAT on 31 October 2010 (or starting OAT within 2
weeks following recruitment).
The association between demographic and clinical features
according to OAT administration at recruitment was evaluated
using the Pearson’s χ2 and Fisher’s test, where appropriate.
The rate of thromboembolic and haemorrhagic events was
computed as total number of events divided by the total
person years at risk.
The Cox regression model was applied to assess the effect
of OAT administration at recruitment on different relevant
end points. For mortality and mortality due to cardiovascular
causes, the models were adjusted for the following potential
confounders: age and dialytic age, gender, antiplatelet therapy
and hypertension status at recruitment, permanent AF and
bleedings/haemorrhagic strokes as time-dependent covariates
(i.e. updated during follow-up). Other variables that were con-
sidered and selected by a backward approach (criteria for
exclusion: P > 0.1) were diabetes mellitus, ischaemic stroke, is-
chaemic heart disease and heart failure (the last three as time-
dependent covariates). The variable bleeding/haemorrhagic
stroke was also considered fixed at the value reported at re-
cruitment, when explicity notified.
The analyses of OAT effect on the hazard of thrombo-
embolic events or on the hazard of haemorrhagic events (first
event) during follow-up were all adjusted by antiplatelet
therapy administration at recruitment while a backward strat-
egy was adopted on all other variables (criteria for exclusion:
P > 0.1). Two additional covariates were considered in the
backward strategy, namely TTR and log(sqrt-VGR) (because
of the skewed distribution), as calculated on the follow-up
time elapsed from recruitment until the occurrence of the first
outcome event. Results of the Cox models are expressed in
terms of estimated hazard ratios (HR), 95% confidence inter-
vals (CI95%) and P-values.
A sensitivity analysis was performed to assess the effect of
confounding by indication of OAT treatment at recruitment
by a propensity score analysis. In particular, propensity scores
were estimated by a logistic regression model with OAT at re-
cruitment as the outcome and all potential confounding vari-
ables as explanatory variables (antiplatelet therapy, age, dialytic
age, gender, permanent AF, hypertension, heart failure, bleed-
ing/haemorrhagic stroke). Patients were then grouped into 10
categories based on quintiles of the estimated propensity scores,
and a Cox regression model was applied to evaluate the effect
of OAT on mortality adjusting by these categories.
The Kaplan–Meier estimator was used to describe survival
in four subgroups defined according to use of OAT at recruit-
ment and therapy shifts during follow-up, and the log-rank
test was used for comparisons of interest. TTR and sqrt-VGR
distributions were described by means of median, interquartile
range and box-plot and whiskers. Analyses were carried out by
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means of the statistical software SAS v.9.2 (SAS Institute Inc.,
Cary, NC, USA), while figures were made by the freeware R
statistical software v.2.12.2 (http://www.r-project.org).
RESULTS
At recruitment, 134 patients out of 290 were taking warfarin
and their characteristics are described in Table 1. Patients with
permanent AF were more likely on OAT (P < 0.001), while
those with previous bleeding (P < 0.001), higher HASBLED
score (P = 0.04) and presence of hypertension (P = 0.05) were
associated with a lower frequency of warfarin prescription.
Patients taking antiplatelet were less likely on OAT (P < 0.001)
and showed higher ischaemic heart disease prevalence
(81/139 = 58% versus 59/151 = 39%, P = 0.001).
Mortality
During the 2-year follow-up, 115 patients died (39.6%), 51
with and 64 without OAT at recruitment, with a 2-year esti-
mated mortality of 37.9% (SE = 4.2) and 41.7% (SE = 4.0),
respectively (log-rank test: P = 0.6). Death was due to cardio-
vascular causes in 36 patients (17 with and 19 without OAT at
recruitment). All causes of death are summarized in Table 2.
As summarized in Table 3, in the multivariate analysis, pa-
tients with or without OAT at recruitment did not differ either
in the hazard of death for any cause (HR = 0.96, CI 0.59–1.56,
P = 0.9), or for cardiovascular death (HR = 1.08, CI 0.47–2.51,
P = 0.9), akin to the results obtained in the univariate analysis.
Among possible confounders, antiplatelet therapy (HR 1.71,
CI 1.10–2.64, P = 0.02) and higher age (≥75 years, 2.08, CI
1.39–3.11, P < 0.001) at recruitment, presence of permanent
AF (HR 2.05, 1.35–3.13, P < 0.001), heart failure (HR 2.06, CI
1.40–3.03, P < 0.001) and bleeding episodes (HR 1.68, CI
1.10–2.57, P = 0.02) were significantly associated with an in-
creased risk of death, while only heart failure was significantly
associated with an increased hazard of cardiovascular death
(HR 3.52, CI 1.67–7.42, P < 0.001, Table 2). When bleedings
indicated only previous haemorrhagic episodes reported at re-
cruitment, the variable was not associated with increased mor-
tality and the relationship between OAT and death was again
not significant (HR = 0.88, CI 0.55–1.44, P = 0.6). The sensi-
tivity analysis confirmed the absence of association between
OAT at recruitment and death (HR = 0.92 CI 0.56–1.52,
P = 0.9) and cardiovascular death (HR = 1.04 CI 0.44–2.44,
P = 0.9).
We found no significant association between OAT at re-
cruitment and age classes; among <75-year-old patients, theHR
of total mortality for OAT at recruitment was 1.66 (CI 0.77–
3.58), P = 0.2, while among >75-year-old patients HR was 0.71
(CI 0.37–1.39), P = 0.32.
Patients continuously taking OAT had an estimated 2-year
survival of 68.6% (SE = 5.0), higher, but not significantly, than
patients who discontinued OAT during follow-up (49.6%, SE
= 7.4, P = 0.07) or who were never exposed to OAT (56.2%, SE
= 4.3, P = 0.1) (Figure 1).
INR and VGR in patients taking OAT
Repeated INR evaluations were available for 149/155 pa-
tients treated with OAT during follow-up. The overall median
Table 1. Patient characteristics by OAT at recruitment
Patient characteristics Total, N (%) OAT at recruitment P-value
No, N (%) Yes, N (%)
Total 290 156 134
Gender
Female 116 (40.0) 68 (43.6) 48 (35.8) 0.2
Male 174 (60.0) 88 (56.4) 86 (64.2)
Age (years)
<65 60 (20.7) 36 (23.1) 24 (17.9) 0.2
65 75 (25.9) 34 (21.8) 41 (30.6)
≥75 155 (53.4) 86 (55.1) 69 (51.5)
Dialytic age (years)
<3 118 (40.7) 64 (41.0) 54 (40.3) 0.9
≥3 172 (59.3) 92 (59.0) 80 (59.7)
Hypertension
Yes 235 (81.0) 133 (85.3) 102 (76.1) 0.05
No 55 (19.0) 23 (14.74) 32 (23.9)
Diabetes mellitus
Yes 91 (31.4) 52 (33.3) 39 (29.1) 0.4
No 199 (68.6) 104 (66.7) 95 (70.9)
Dyslipidaemia
Yes 93 (32.1) 44 (28.2) 49 (36.6) 0.1
No 197 (67.9) 112 (71.8) 85 (63.4)
Peripheral artery disease
Yes 201 (69.3) 106 (68.0) 95 (70.9) 0.6
No 89 (30.7) 50 (32.0) 39 (29.1)
Ischaemic heart disease
Yes 140 (48.3) 79 (50.6) 61 (45.5) 0.4
No 150 (51.7) 77 (49.4) 73 (54.5)
Heart failure
Yes 115 (39.7) 57 (36.5) 58 (43. 3) 0.2
No 175 (60.3) 99 (63.5) 76 (56.7)
Ischaemic stroke
Yes 43 (14.8) 22 (14.1) 21 (15.7) 0.7
No 247 (85.2) 134 (85.9) 113 (84.3)
Bleeding/Haemorrhagic stroke
Yes 57 (19.7) 41 (26.3) 16 (11.9) 0.002
No 233 (80.3) 115 (73.7) 118 (88.1)
Atrial fibrillation
Paroxysmal 59 (20.4) 46 (29.5) 13 (9.7) <0.001
Persistent 130 (44.8) 77 (49.4) 53 (39.6)
Permanent 101 (34.8) 33 (21.1) 68 (50.7)
Thromboembolic pulmonary disease
Yes 8 (2.8) 5 (3.2) 3 (2.2) 0.7a
No 282 (97.2) 151 (96.8) 131 (97.8)
Antiplatelet therapy
Yes 139 (47.9) 112 (71.8) 27 (20.2) <0.001
No 151 (52.1) 44 (28.2) 107 (79.8)
Low-molecular-weight heparin
Yes 12 (4.1) 7 (4.5) 5 (3.7) 0.7
No 278 (95.9) 149 (95.5) 129 (96.3)
CHA2DS2VASCS
0–1 12 (4.1) 9 (5.8) 3 (2.2) 0.08
2–4 149 (51.4) 72 (46.1) 77 (57.5)
5–9 129 (44.5) 75 (48.1) 54 (40.3)
HASBLEDb
0–1 3 (1.0) 1 (0.6) 2 (1.5) 0.04a
2–3 96 (33.1) 43 (27.6) 53 (39.5)
4–9 191 (65.9) 112 (71.8) 79 (59.0)
aFisher’s test.
bIt does not include the score related to labile INR, because unavailable at recruitment.
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TTR was 54% (IQR 41–67%). Patients taking OAT without
discontinuation had the highest TTR (median = 60%, IQR 45–
71%), while those who discontinued therapy and those who
started OAT during follow-up had similar TTR distributions
(Figure 2).
Overall, INR variability (estimated according to standard
deviation, i.e. square root of VGR, sqrt-VGR) results were not
normally distributed with the median equal to 0.92 (IQR:
0.61–1.60). Patients treated with OAT during the whole
follow-up had a median sqrt-VGR equal to 0.77 (IQR: 0.55–
1.07), while those who did not take OAT continuously had a
more spread VGR (Figure 2).
Thromboembolic events
During follow-up, 17 thromboembolic events occurred in
15 patients (16 ischaemic strokes and 1 thromboembolic pul-
monary disease). Six events (35.3%) occurred in patients cur-
rently assuming OAT: INR was <2 in four cases (66.7%) and
between 2 and 3 in the other two cases (33.3%). OAT was not
associated with a significant decrease in the risk of thrombo-
embolic events in the multivariate model (HR = 0.12, CI 0.00–
3.59, P = 0.2). The only factor feebly associated with thrombo-
embolic events was higher age (≥75 years) (HR 3.01, CI 0.81–
11.18, P = 0.1).
Haemorrhagic events
During follow-up, 67 events occurred in 42 patients and 24
of them (57.1%) experienced bleeding when taking OAT. Of
the three haemorrhagic strokes, one occurred in a patient tak-
ing antiplatelet therapy, one in a patient treated with low-
molecular-weight heparin and one in a patient treated with
both drugs. Out of 42 patients with haemorrhagic events during
follow-up, 14 had other bleeding episodes before recruitment.
As summarized in Table 4, OAT is seen to be associated
with an increased risk of haemorrhagic events (HR 3.96, CI
1.15–13.68, P = 0.03) after adjustment for possible confoun-
ders. Patients who experienced bleeding before recruitment
had a higher risk of new haemorrhagic events (HR 2.17, CI
1.09–4.35, P = 0.03), so the higher the TTR, the lower the
haemorrhagic risk (HR 0.09, CI 0.01–0.76, P = 0.03). In the
228 patients who had not experienced bleeding before recruit-
ment, the increased haemorrhagic risk during follow-up due
to OAT was confirmed (HR = 4.81, CI 1.08–21.35, P = 0.04),
such as the protective effect of higher TTR (HR = 0.07, CI
0.01–0.80, P = 0.03). In the 56 patients who had haemorrhagic
events before recruitment, none of the previous factors seemed
to affect the risk of onset of new haemorrhagic events.
Predictive ability of thromboembolic and haemorrhagic
risk scores
The rate of thromboembolic events increased with CHA2-
DS2VASc score and patients with low CHA2DS2VASc (0–1)
had no events. An increment of the rate of major bleeding
with increasing HASBLED was also observed (Table 5).
DISCUSSION
In a cohort of chronic HD patients with AF, OAT is not asso-
ciated with total mortality, while antiplatelet agents are
associated with an increased risk of death of ∼70% more. The
continuous use of warfarin tends to be associated with
improved survival as compared with individuals who discon-
tinued the medication during follow-up, but the incidence of
thromboembolic events is not different in OAT subjects as
compared with those who do not take it. Moreover, bleeding
Table 2. Causes of death stratified by OAT at recruitment
Total, N (%) OAT at recruitment
No (n = 156),
N (%)
Yes (n= 134),
N (%)
Alive 175 (60.3) 92 (59) 83 (62)
Dead 115 (39.7) 64 (41) 51 (38)
Cause of death
Sudden cardiac death 17 (5.9) 7 (4.5) 10 (7.5)
Acute pulmonary oedema 1 (0.3) 1 (0.6) 0 (0)
Cardiogenic shock 13 (4.5) 8 (5.1) 5 (3.7)
Ischaemic stroke 1 (0.3) 1 (0.6) 0 (0)
Haemorrhagic stroke 3 (1) 1 (0.6) 2 (1.5)
Sepsis 25 (8.6) 14 (9) 11 (8.2)
Neoplasia 8 (2.8) 6 (3.9) 2 (1.5)
Cachexia 32 (11) 16 (10.3) 16 (11.9)
Other causes 15 (5.2) 10 (6.4) 5 (3.7)
Table 3. Cox model on the death risk for any cause and on cardiovascular death risk adjusted by relevant covariates
Death for any cause Cardiovascular death
HR CI95% P-value HR CI95% P-value
OAT: yes versus no 0.96a 0.59–1.56 0.9 1.08b 0.47–2.51 0.9
Antiplatelet therapy: yes versus no 1.71 1.10–2.64 0.02 1.77 0.83–3.78 0.1
Age ≥75 years versus <75 years 2.08 1.39–3.11 <0.001 1.51 0.76–3.02 0.2
Dialytic age ≥3 years versus <3 years 0.9 0.61–1.31 0.6 1.27 0.64–2.53 0.5
Gender: female versus male 0.71 0.49–1.04 0.08 0.85 0.43–1.71 0.7
Permanent AF versus other AF 2.05 1.35–3.13 <0.001 1.78 0.84–3.77 0.1
Hypertension: yes versus no 1.26 0.77–2.07 0.4 1.14 0.49–2.67 0.8
Heart failure: yes versus no 2.06 1.40–3.03 <0.001 3.52 1.67–7.42 <0.001
Bleeding/haemorrhagic stroke: yes versus no 1.68 1.10–2.57 0.02 1.57 0.74–3.32 0.2
OAT, oral anticoagulant therapy; AF, atrial fibrillation.
aThe corresponding estimated HR in a model without adjustment by other covariates was HR = 0.90 (P-value = 0.6).
bThe corresponding estimated HR in a model without adjustment by other covariates was HR = 1.01 (P-value = 0.9).
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events are more frequent in patients taking warfarin, although
the maintenance over time of an INR in the therapeutic range
wards against the risk of bleeding.
Studies regarding OAT use in AF patients with ESRD are
relatively few and they do not reach conclusive results. Some
studies are based on large databases, but they also draw con-
clusions from retrospectively collected and analysed registry
data [10, 12, 13] or from a post hoc analyses made on the
results of trials designed for other purposes [11, 14].
Our prospective study suggests a reduction in the mortality
risk in HD patients with documented AF on OAT therapy.
This result contrasts with Chan’s data, showing an increased
mortality in a population of ESRD patients treated with war-
farin [18]. However even in this study, the analysis, restricted
solely to AF patients receiving OAT, does not show any in-
crease in deaths [10]. A revision of data from the DOPPS
shows an excess of mortality in patients treated with warfarin
or ticlopidine, but a mortality analysis on the subpopulation of
patients with AF is lacking [14]. In our population, warfarin is
not associated with a higher death risk, even though subjects
with permanent AF most frequently take OAT, and permanent
AF represents an important mortality predictor. Moreover,
patients who continue to take OAT have lower mortality as
compared with those who suspend it during the follow-up,
often due to a bleeding. The latter is a factor independently as-
sociated with increased mortality and thus our data suggest an
advantage in terms of survival for those patients who are able
to continue taking the medication with no side effects. It is
possible that our patients taking OAT, particularly those who
have taken it for the entire follow-up, were healthier at recruit-
ment and thus the improved prognosis was not due to the
effect of warfarin treatment alone. However, results similar to
ours have recently been found in a population of chronic
kidney disease patients with AF [19]. Unlike warfarin, antipla-
telet agents are associated with an increased risk of mortality,
confirming what had been observed in other ESRD popula-
tions [14, 18]. However, this could be due not only to antipla-
telet agents per se but to the higher prevalence of ischaemic
heart disease in this group of patients, which could make them
more vulnerable.
F IGURE 2 : TTR and the squared root of VGR distributions by OAT administration during follow-up. The box represents the first and third
quartile, the central line the median, the white square the mean and the whiskers are located at the maximum and minimum observation
(outside observations indicated with dots are those out of the 1.5× interquartile range); the dashed line represents the overall median. Therapy
group: 1 = OAT at recruitment and during the whole follow-up; 2 = OAT at recruitment, but interrupted during the follow-up; 3 = no OAT at re-
cruitment, but assumed during the follow-up 1 + 2 = OAT at recruitment (intention to treat).
F IGURE 1 : Kaplan–Meier curves for survival according to oral
anticoagulant therapy (OAT) accounting for therapy shift during the
2 years of follow-up. Therapy group: 1 = OAT at recruitment and
during the whole follow-up; 2 = OAT at recruitment, but interrupted
during the follow-up; 3 = no OAT at recruitment, but taken during
the follow-up; 4 = neither OAT at recruitment nor during the whole
follow-up. Log-rank test P-value between couples of therapy group: 1
versus 2 = 0.07; 1 versus 4 = 0.1.
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The majority of deaths in our patients are not due to stroke
and are often non-cardiac deaths, as previously observed in
other populations of AF patients with and without ESRD [20–
22]. These results emphasize the need to identify effective in-
terventions that go beyond anticoagulation to reduce further
high mortality in the AF population.
In our study, patients taking warfarin show a slight, non-
significant, reduction of thromboembolic events. Some authors
described an increased risk of strokes in HD patients with AF
taking warfarin [10, 11], while others see no effect [12] and
Olesen et al. [13] reported a reduction of thromboembolic
events. In these studies, unlike in our study, the ischaemic or
haemorrhagic nature of the cerebrovascular episodes is not
always documented. In our patients, the thromboembolic event
rate was 3.7%, not higher than expected according to the cal-
culated CHA2DS2VASc score and similar in subjects both
taking and not taking OAT. These data are comparable with
those previously reported by Wizemann et al. [11]. Possibly in
HD patients the presence of platelet dysfunction could reduce
thromboembolic risk, even in subjects who are not taking
OAT. Another possible protective factor is the use of heparin
during dialysis, with an anticoagulant effect that may extend
for several hours after the dialysis session. However, the fact
that although half of the population did not take warfarin, the
time of INR in the therapeutic range among treated patients is
∼50% and almost all patients experiencing a thromboembolic
event were either not on OAT or had an INR <2, which does
not allow us to understand whether proper warfarin adminis-
tration has a role in preventing thromboembolic events in pa-
tients with ESRD and AF.
Even in our population, as already reported [12, 23, 24],
OAT is associated with an increased haemorrhagic risk. This
seems to be a good enough reason to discourage the nephrolo-
gist from using warfarin, even when there is an indication for
prescription [25]. However, our data show that patients main-
taining INR in the therapeutic range are protected from bleed-
ing complications. Hence, the increased haemorrhagic risk
does not seem to be so much due to the warfarin per se as to
the difficulties encountered in maintaining a proper thera-
peutic INR range. However, a high TTR does not seem to be
protective in patients with previous bleeding. Our findings
confirm that HD patients are at high risk for both thrombosis
and bleeding, and that any OAT treatment needs to be per-
formed with great care. In particular, warfarin should not be
Table 5. Rate per 100 patients-years of thromboembolic and haemorrhagic events during follow-up according to CHA2DS2VASc and HASBLED scores and
OAT at recruitment
Thromboembolic
events
CHA2DS2VASc
0–1 (N = 12) 2–4 (N = 149) 5–9 (N = 129) Overall (N = 290)
Number of
patients
Number of
events
Rate Number of
patients
Number of
events
Rate Number of
patients
Number of
events
Rate Number of
patients
Number of
events
Rate
Overall 12 0 0 149 6 2.4 129 11 5.8 290 17 3.7
OAT yes 3 0 0 77 3 2.3 54 5 6.4 134 8 3.7
OAT no 9 0 0 72 3 2.6 75 6 5.3 156 9 3.7
Haemorrhagic
events
HASBLED
0–1 (N = 3) 2–3 (N = 97) 4–9 (N = 190) Overall (N = 290)
Number of
patients
Number of
events
Rate Number of
patients
Number of
events
Rate Number of
patients
Number of
events
Rate Number of
patients
Number of
events
Rate
Overall 3 0 0 97 20 12.6 190 47 15.9 290 67 14.5
OAT yes 2 0 0 60 18 17.8 72 20 18 134 38 17.6
OAT no 1 0 0 37 2 3.5 118 27 14.6 156 29 11.8
Table 4. Cox model results on hazard of haemorrhagic events
Haemorrhagic events
Total population, number of
patients = 284, number of
events = 40
No before recruitment, number
of patients = 228, number of
events = 27
Yes before recruitment,
number patients = 56, number
of events = 13
HR CI95% P HR CI95% P HR CI95% P
OAT: yes versus no 3.96 1.15–13.68 0.03 4.81 1.08–21.35 0.04 2.21 0.17–28.73 0.5
Antiplatelet therapy: yes versus no 0.86 0.41–1.80 0.7 0.75 0.29–1.96 0.6 1.09 0.33–3.61 0.9
TTR 0.09 0.01–0.76 0.03 0.07 0.01–0.80 0.03 0.2 0.00–18.04 0.5
Bleeding/haemorrhagic stroke: yes versus no 2.17 1.09–4.35 0.03
OAT, oral anticoagulant therapy; TTR, target therapeutic range.
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administered in patients with previous bleeding episodes oc-
curring in the presence or even in the absence of OAT. In
these subjects, particularly when the CHA2DS2VASc score is
high, alternative hypotheses for the prevention of thrombo-
embolism, recently proposed in cardiology, i.e. the closure of
the left atrial appendage [26], could be evaluated.
In our study, low CHA2DS2VASc and HASBLED scores
identify patients at lower thromboembolic or haemorrhagic
risk confirming that these scores, even in subjects with ESRD,
may provide consistent data [11, 12]. A better performance of
the CHADS2 score when two points were added in patients
with a glomerular filtration rate <45 mL/min has been shown
[27]. Studies that lead to a modification of the thromboembol-
ic scores based on the presence of renal disease are warranted
and careful evaluation of the HASBLED score before embark-
ing on an OAT in a patient with ESRD definitely remains of
paramount clinical importance.
The strengths of this study are that cerebrovascular events
were always defined as ischaemic or haemorrhagic by com-
puted tomographic scan or nuclear magnetic resonance, and
that the INR was carefully monitored. A limitation is the fact
that this was not a randomized study and the nephrologist was
left to choose the therapeutic prescription without reservation:
OAT, antiplatelet therapy or nothing.
In conclusion, to our knowledge, this is the first prospective
study designed to assess the effects of warfarin on both mortal-
ity and cerebrovascular events in HD population. In our study,
OAT is not associated with increased mortality; although it is
not related to a significant decreased incidence of ischaemic
stroke, it increases the incidence of bleeding. However, in our
population, the risk of bleeding is reduced in subjects in whom
INR is constantly kept within the therapeutic range. More-
over, the thromboembolic (CHA2DS2VASc) and haemor-
rhagic (HASBLED) scores are capable of identifying low-risk
patients, but this population represents a minority of the sub-
jects being examined. Many of our findings may be useful with
regard to the controversial issue of anticoagulation in HD
patients with AF. Larger prospective studies and randomized
trials are greatly needed to provide nephrologists with add-
itional elements concerning how to treat HD patients with AF
in order to prevent the thromboembolic complications of the
arrhythmia avoiding the haemorrhagic risk related to OAT in
these patients with such a high risk of bleeding.
SUPPLEMENTARY MATERIAL
Supplementary material is available online at http://ndt.oxford
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ABSTRACT
Background. In elderly hemodialysis (HD) patients, the risk
of medication-related problems is particularly high. Thus,
certain medications should generally not be prescribed to
those patients. The Beers criteria for potentially inappropriate
medications (PIMs) have been publicized. Still, with regard to
elderly HD patients, the prevalence and risk factors for pre-
scription of PIMs are unknown.
Methods. This was a cross-sectional study of data from the
Japan Dialysis Outcomes and Practice Patterns Study (2002–
08). Patients were included if they were 65 years old or older
and were currently receiving HD treatment at a hospital or
clinic. We counted the number of patients who were prescribed
at least one PIM, as defined by the modified Beers criteria. We
used multiple logistic regression analysis to determine which
patient characteristics and facility characteristics were associated
with prescription of PIMs.
Results. Data from 1367 elderly patients were analyzed. More
than half of the patients (57%) had been prescribed a PIM.
The three most frequently prescribed PIMs were H2 blockers
(33%), antiplatelet agents (19%) and α-blockers (13%). PIM
prescriptions were less likely at facilities that conducted multi-
disciplinary rounds {adjusted odds ratio (AOR): 0.67 [95%
confidence interval (CI): 0.48–0.93]} and at teaching hospitals
[AOR: 0.59 (95% CI, 0.39–0.90)]. PIM prescriptions are more
likely if more than one physician has clearance to alter the HD
regimen [AOR: 1.65 (95% CI, 1.12–2.44)].
Conclusions. PIMs were prescribed to many elderly HD pa-
tients in Japan. Nephrologists should become more aware
of PIMs. Multidisciplinary rounds could benefit patients by
reducing the prescription of PIMs.
Keywords: adverse drug events, DOPPS, elderly patients,
hemodialysis, potentially inappropriate medication
INTRODUCTION
Issues associated with medication administration remain a major
healthcare concern, particularly among elderly patients. A 2005
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